Clinical Trial Update: Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease [Phase 1, Phase 2]

View source ↗

Summary

Acepodia Biotech is conducting a Phase 1/2 clinical trial to assess safety, efficacy, and persistence of ACE1831 in IgG4-related disease, with recruitment ongoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Igg4-related Disease

Drugs mentioned

• ACE1831

Snippet

Sponsor: Acepodia Biotech, Inc. | Conditions: IgG4 Related Disease | Phase 1, Phase 2 | Status: RECRUITING